COVID-19

LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System

CAMBRIDGESHIRE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) -- LEX Diagnostics, a leading innovator in molecular diagnostics, has submitted dual…

7 months ago

Nanox Receives MDR CE Mark for HealthOST, an Advanced AI-Powered Software for Spine Assessment

HealthOST identifies vertebral height loss and bone mineral density, which are key indicators of musculoskeletal diseaseOsteoporosis is a common progressive…

7 months ago

Mindset Medical Announces FDA Clearance for its Contactless Respiratory Rate Measurement Device

PHOENIX, June 4, 2025 /PRNewswire/ -- Mindset Medical, Inc. ("Mindset Medical" or the "Company"), a digital health company, today announced…

7 months ago

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response  Results, presented…

7 months ago

Manufacturing PMI® at 48.5%; May 2025 Manufacturing ISM® Report On Business®

New Orders and Backlogs Contracting; Production and Employment Contracting; Supplier Deliveries Slowing; Raw Materials Inventories Contracting; Customers' Inventories Too Low;…

7 months ago

Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality

This major Swoop® system scanner redesign and Optive AI™ software elevate the AI-powered portable MRI experience for clinicians and their…

7 months ago

Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality

This major Swoop® system scanner redesign and Optive AI™ software elevate the AI-powered portable MRI experience for clinicians and their…

7 months ago

Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to…

7 months ago

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless…

7 months ago